Sentiment-Signal
18,3
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
Unternehmen & Branche
| Name | PALVELLA THERAPEUTICS, INC. |
|---|---|
| Ticker | PVLA |
| CIK | 0001583648 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,52 Mrd. USD |
| Beta | -0,20 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -41,715,000 | -3.71 | 59,559,000 | 27,983,000 | |
| 2025-09-30 | 10-Q | -11,345,000 | -1.03 | 66,937,000 | 38,682,000 | |
| 2025-06-30 | 10-Q | -9,471,000 | -0.86 | 73,747,000 | 47,780,000 | |
| 2025-03-31 | 10-Q | -8,185,000 | -0.74 | 79,439,000 | 55,577,000 | |
| 2024-12-31 | 10-K | -17,434,000 | -7.83 | 88,234,000 | 62,607,000 | |
| 2024-12-31 | 10-Q | -17,400,000 | 88,234,000 | 62,607,000 | ||
| 2024-09-30 | 10-Q | 0 | -6,775,000 | -3.94 | 20,522,000 | -87,404,000 |
| 2024-06-30 | 10-Q | 0 | -4,172,000 | -2.47 | 25,051,000 | -80,828,000 |
| 2024-03-31 | 10-Q | 53,000 | -2,536,000 | -1.54 | 29,497,000 | -76,873,000 |
| 2023-12-31 | 10-K | 42,810,000 | 18,691,000 | 2.17 | 7,548,000 | -74,483,000 |
| 2023-09-30 | 10-Q | 19,520,000 | -10,752,000 | -8.70 | 59,376,000 | 30,510,000 |
| 2023-06-30 | 10-Q | 20,055,000 | 3,976,000 | 3.62 | 87,544,000 | 40,498,000 |
| 2023-03-31 | 10-Q | 1,936,000 | -13,183,000 | 82,258,000 | 15,458,000 | |
| 2022-12-31 | 10-K | 25,902,000 | -33,277,000 | 95,490,000 | -93,777,000 | |
| 2022-09-30 | 10-Q | 5,370,000 | -9,736,000 | 99,163,000 | 35,767,000 | |
| 2022-06-30 | 10-Q | 3,698,000 | -10,338,000 | -0.14 | 114,309,000 | 44,365,000 |
| 2022-03-31 | 10-Q | 10,988,000 | -5,101,000 | -0.07 | 137,115,000 | 53,450,000 |
| 2021-12-31 | 10-K | 31,418,000 | -45,738,000 | -0.71 | 153,560,000 | 50,755,000 |
| 2021-09-30 | 10-Q | 4,057,000 | -16,536,000 | -0.24 | 164,184,000 | 53,853,000 |
| 2021-06-30 | 10-Q | 3,285,000 | -15,498,000 | -0.25 | 155,030,000 | 46,721,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-15 | Goin Kathleen | Officer, Chief Operating Officer | Open Market Sale | -100 | 130.33 | -13,033.00 | -7,5% | |
| 2026-04-15 | Goin Kathleen | Officer, Chief Operating Officer | Open Market Sale | -1,502 | 125.96 | -189,198.98 | -109,0% | |
| 2026-04-15 | Goin Kathleen | Officer, Chief Operating Officer | Open Market Sale | -1,500 | 127.13 | -190,688.10 | -109,9% | |
| 2026-04-15 | Goin Kathleen | Officer, Chief Operating Officer | Open Market Sale | -639 | 129.17 | -82,539.12 | -47,6% | |
| 2026-04-15 | Goin Kathleen | Officer, Chief Operating Officer | Open Market Sale | -561 | 128.23 | -71,939.78 | -41,5% | |
| 2026-03-18 | Goin Kathleen | Officer, Chief Operating Officer | Open Market Sale | -304 | 119.08 | -36,200.84 | -20,9% | |
| 2026-03-18 | Goin Kathleen | Officer, Chief Operating Officer | Open Market Sale | -1,730 | 118.37 | -204,776.81 | -118,0% | |
| 2026-03-18 | Goin Kathleen | Officer, Chief Operating Officer | Open Market Sale | -2,268 | 117.56 | -266,633.34 | -153,7% | |
| 2026-02-18 | Goin Kathleen | Officer, Chief Operating Officer | Open Market Sale | -1,276 | 79.97 | -102,035.47 | -58,8% | |
| 2026-02-18 | Goin Kathleen | Officer, Chief Operating Officer | Open Market Sale | -3,026 | 79.16 | -239,528.78 | -138,1% | |
| 2026-01-21 | Goin Kathleen | Officer, Chief Operating Officer | Open Market Sale | -3,749 | 97.94 | -367,177.06 | -211,6% | |
| 2026-01-21 | Goin Kathleen | Officer, Chief Operating Officer | Open Market Sale | -553 | 95.49 | -52,805.97 | -30,4% | |
| 2025-12-17 | Goin Kathleen | Officer, Chief Operating Officer | Open Market Sale | -4,302 | 96.47 | -415,022.54 | -239,2% | |
| 2025-11-19 | Goin Kathleen | Officer, Chief Operating Officer | Open Market Sale | -1,500 | 85.72 | -128,577.45 | -74,1% | |
| 2025-11-19 | Goin Kathleen | Officer, Chief Operating Officer | Open Market Sale | -2,802 | 86.51 | -242,387.85 | -139,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.